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Objective:
 
 The assessment of relationships between particularities of dys-
lipidemia (DL) and arterial hypertension (H).
 
Methods:
 
 184 patients (pts) (85 males and 99 females, average age
52.5±3.5 years) with different cardiovascular pathology (excluding acute cor-
onary syndrome) were enrolled in the study. DL without H was the criterion
of inclusion to the study. The evaluation of total cholesterol (TC), low density
lipoproteins (LDL) cholesterol, very low density lipoproteins (VLDL) choles-
terol, high density lipoproteins (HDL) cholesterol and triglycerides (TG) was
done as obligatory test. The investigations were performed every 6 months
during 3 years.
 
Results:
 
 The pts were divided into 3 groups (grs) according to time of H
development. 48 pts (26.1%) with history of H during 1st year of follow-up
were included in 1 gr. 43 pts (23.4%) with history of H during 2nd year of
follow-up were included in 2 gr. 55 pts (29.9%) with history of H during 3rd
year of follow-up were included in 3 gr. 38 pts (20.7%) without H during 3rd
year of follow-up were included in 4 gr. The TG elevation was detected in
69% of pts in 1 gr (1.98±0.08 mmol/l), 60% of pts in 2 gr (1.90±0.1 mmol/l)
and 54% of pts in 3 gr (1.87±0.09 mmol/l).
The combined elevation of TG and LDL-cholesterol was detected in 63%
of pts in 1 gr (1.96±0.10 mmol/l and 4.54±0.08 mmol/l), in 55% of pts in 2 gr
(1.90±0.07 mmol/l and 4.22±0.12 mmol/l), in 63% of pts in 1 gr (1.86±0.09
mmol/l and 4.08±0.08 mmol/l). Pts from 4 gr had isolated elevation of TC (18
pts (47.4%) – 6.84±0.09 mmol/l), combined elevation of TC and VLDL-cho-
lesterol (11 pts (28.9%), 6.72±0.07 mmol/l and 0.65±0.07 mmol/l, accord-
ingly), combined elevation of LDL-cholesterol and VLDL-cholesterol (9 pts
(23.7%), 4.12±0.06 mmol/l and 0.52±0.07 mmol/l, accordingly)
 
Conclusions: 
 
The elevated level of TG is the most significant factor for
origin of H. Further progression of H is related to TG and LDL-cholesterol
levels. 
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Introduction: While there are much data on the risk factors involved in the
onset of atherothrombotic stroke (AS) or acute coronary syndrome (ACS), few
studies have compared the prevalence of metabolic syndrome (MS) and insulin
resistance (IR) in the occurrence of these events.
Methods: In a pilot study, prospective, comparative, single centre, 137
patients who presented an AS (N= 68) or ACS (N= 69) were consecutively
included. The cardiovascular risk factors (CRF) were collected, the prevalence
of MS was determined using « the National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATPIII) and the International Diabetes Fed-
eration (IDF) definitions. IR was determined using the homeostasis model
assessment of insulin resistance (HOMA-IR) in patients without insulin treat-
ment.
Results: There were no significant differences between groups for history
of hypertension or diabetes, cardiovascular heredity, body mass index, nor
lipid parameters. Sex ratio was similar in both groups but AS patients were
older (58.2±8.4 vs. 54.0±8.8 respectively, p=0.006. Active smoking was more
prevalent in the ACS group (30 vs. 18%, p=0.04). Plasma glucose and insulin
levels were higher in the ACS group (5.59±1.86 vs. 5.0±1.0 mmol/l, p=0.04;
9. ±1.04 vs. 6.7±3.6 µUI/ml, p=0.04, respectively). There was no difference in
the prevalence of MS between ACS and AS groups, using NCEP-ATPIII defi-
nition (11 vs. 12 %, p=NS) or IDF definitions (26 vs. 23%, p=NS). There was
a significantly higher IR in the ACS group (HOMA-IR 2.17+1.90 vs.
1.50+0.81, p=0.03). 
Conclusion: In our study, distribution of cardiovascular risk factors is dif-
ferent according to the athero-thrombotic disease. The metabolic disturbances
in particular IR seems to be predominant in the onset of ACS.
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Background: The traditional method of calculation of the ankle-brachial
index (ABI) and the usual 0.90 threshold have been recently challenged by
alternate methods and values proposed as more sensitive to predict cardiovas-
cular mortality. However the overall discriminative value of the ABI using dif-
ferent modes of calculation has not been systematically performed.
Methods: We assessed the ABI to predict the 5-years mortality of 705
patients who underwent coronary bypass surgery. We  compared the ROC
curves of 6 modes of ABI calculation, combining 3 different numerators (the
highest (high), the mean (mean) and the lowest (low) pressure of posterior
tibial and anterior tibial arteries) with 2 denominators (the highest (high) or the
mean (mean) systolic pressure of both arms).
Results: During follow-up, 97 (13.8%) patients died. The area under the
curves (AUC) of the 6 methods to predict 5-years mortality were similar
(Table). Only the AUC of method “High/High” was significantly (p<0.05)
higher than method “High/Mean” and “Low/Mean”. The most accurate
threshold to predict mortality differed for each method.
Conclusion: Each mode of ABI calculation presents its own optimal cut-
off value to predict mortality. The use of the single 0.90 threshold to compare
different modes of ABI calculation is inappropriate. The ABI mode of calcu-
lation and the threshold should be considered altogether. The ability of the
ABI to predict mortality is almost similar among different modes of calcula-
tion.
(Voir tableau page suivante)
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Background: Patients with critical limb ischemia (CLI) unsuitable for
revascularization have a high rate of amputation and mortality (30% and 25%
at 1 year respectively Local gene therapy using plasmid DNA encoding acidic
fibroblast growth factor (NV1FGF, riferminogene pacaplasmid) showed prom-
ising results in a phase II trial on amputation free survival. This report pro-
vides the rationale, design and baseline characteristics of CLI patients enrolled
